Structural Changes of Sodium Warfarin in Tablets Affecting the Dissolution Profiles and Potential Safety of Generic Substitution
Open Access
- 30 August 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (9) , 1364
Abstract
At present, the risk of generic substitutions in warfarin tablets is still being discussed. The aim of this study was to assess whether API interactions with commonly used excipients may affect the safety of generic replacement of warfarin sodium tablets. These interactions were observed during an accelerated stability study, and the effect of the warfarin solid phase (crystalline/amorphous form) as well as the API particle size distribution was studied. Commercial tablets and prepared tablets containing crystalline warfarin or amorphous warfarin were used. In addition, binary mixtures of warfarin with various excipients were prepared. The structural changes before and after the stability study were monitored by dissolution test in different media, solid-state NMR spectroscopy and Raman microscopy. During the stability study, the conversion of the sodium in warfarin to its acid form was demonstrated by some excipients (e.g., calcium phosphate). This change in the solid phase of warfarin leads to significant changes in dissolution, especially with the different particle sizes of the APIs in the tablet. Thus, the choice of suitable excipients and particle sizes are critical factors influencing the safety of generic warfarin sodium tablets.Keywords
Funding Information
- Ministry of Education, Youth and Sports of the Czech Republic (LTAUSA18011)
- Masarykova Univerzita (MUNI/A/1574/2020)
This publication has 43 references indexed in Scilit:
- Characterization of solid polymer dispersions of active pharmaceutical ingredients by 19F MAS NMR and factor analysisSpectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2013
- Bleeding Risk with Dabigatran in the Frail ElderlyNew England Journal of Medicine, 2012
- Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) TrialCirculation, 2012
- New perspectives of 19F MAS NMR in the characterization of amorphous forms of atorvastatin in dosage formulationsInternational Journal of Pharmaceutics, 2011
- Binding Strength of Sodium Ions in Cellulose for Different Water ContentsThe Journal of Physical Chemistry B, 2008
- Warfarin Therapy: Influence of Pharmacogenetic and Environmental Factors on the Anticoagulant Response to Warfarin2008
- Thrombolytics, Anticoagulants, and Antiplatelet AgentsStroke, 2006
- Generic Warfarin: Implications for Clinical Practice and Perceptions of Anticoagulation ProvidersSeminars in Thrombosis and Hemostasis, 2004
- Physical chemical stability of warfarin sodiumAAPS PharmSci, 2001
- The crystal and molecular structure and absolute configuration of (−)-(S)-warfarinActa Crystallographica Section B: Structural Science, Crystal Engineering and Materials, 1975